Computer-based thinking tasks in people with schizophrenia or schizoaffective disorder and healthy adults
Tests computer thinking tasks in adults with schizophrenia, schizoaffective disorder, and healthy adults.
Plain-language title generated from the registry record
Registry title: Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2
Key facts
- Where
- Baltimore, Chicago, Irvine, Minneapolis, and St Louis, United StatesSee the 5 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 59 years old?
Source: NCT07875790, who can take part
Where in United States
- University of Maryland, BaltimoreBaltimore, United StatesNo longer taking part
- The University Of ChicagoChicago, United StatesNo longer taking part
- University of California, IrvineIrvine, United StatesNo longer taking part
- University of MinnesotaMinneapolis, United StatesNo longer taking part
- Washington UniversitySt Louis, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Washington University School of Medicine
- Trial code
- NCT07875790
- Record updated
- 9 November 2026
- Original description
In Study 2, investigators will recruit individuals with schizophrenia (SZ) and or schizoaffective disorder (SZA) and healthy controls (HC) using optimized behavioral tasks to replicate the behavioral findings from Study 1 and to assess additional psychometric properties such as test re-test reliability and practice effects.Read full original descriptionShow less
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium
In Study 2, investigators will recruit individuals with schizophrenia (SZ) and or schizoaffective disorder (SZA) and healthy controls (HC) using optimized behavioral tasks to replicate the behavioral findings from Study 1 and to assess additional psychometric properties such as test re-test reliability and practice effects.
Investigators will obtain data on: A) clinical symptoms, with detailed assessment of hallucinations and delusions; B) community functioning; and C) functional capacity, allowing us to examine clinical validity. To generate a sample with sufficient variation in hallucinations and delusions, investigators will recruit the following groups that balance feasibility with clinical relevance: A) healthy controls [HC, N=125]; B) schizophrenia and schizoaffective disorder [SZ/SZA, N=200]). Investigators anticipate a ~20% screen fail/drop-out rate based upon prior studies. Thus, investigators will run an additional 40 SZ/SZA and 15 HC.
Investigators will administer tasks optimized in Aim 1 without electroencephalogram (EEG), to this new sample of individuals with SZ/SZA and HC.
All participants will be retested after approximately 28 days and repeat clinical assessments. Although the investigators' goal is to shorten task length using the Study 1 analyses, they will administer longer tasks than optimal for public dissemination in Study 2 to determine the minimum number of trials required for acceptable reliability. Study 2 will use the same clinical and functional measures as Study 1.
Inclusion: General Inclusion; age 18 to 59 ; no substance disorder in past six months (confirmed with urine drug screens and breathalyzers); no clinically significant head injury or neurological disease; WechslerTest of Adult Reading (WTAR) score =16+; Group Specific Criteria: Schizophrenia/SchizoaffectiveDisorder (SZ/SZA):; Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnosis ofschizophrenia or schizoaffective; no medication changes in prior month or anticipated in the next month or not taking medications; outpatient or partial hospital if unmedicated; Healthy Controls (HC):; no Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) - Psychosis or BipolarDisorder; no family history of psychosis or bipolar.
Exclusion: self-reported medication non-compliance for at least the four previous weeks; never having started medications; Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)Psychosis or Bipolar Disorder diagnosis; Family history of psychosis, bipolar, or Schizophrenia/Schizoaffective Disorder (SZ/SZA); additional exclusion criteria for the unmedicated individuals are:; Healthy Controls (HC):; not in acute exacerbation requiring immediate hospitalization or treatment.